Novartis Investigative Site

Leiden, South Holland 2333 ZA

2 studies enrolling now · 13 studies all time

What they study most

Advanced Solid Tumors, Advanced, Metastatic Breast Cancer, Ankylosing Spondylitis, Atherosclerotic Cardiovascular Disease, C3 Glomerulopathy, C3G, Cardiovascular Disease and Lipoprotein(a), Familial Hypercholesterolemia, Immune-complex-membranoproliferative Glomerulonephritis, Lupus Erythematosus, Systemic, Lupus Nephritis, Melanoma

Studies at this site

• Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN — Recruiting now
• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. — Recruiting now
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — Recruiting now
• Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments — Running, not enrolling
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma — Stopped early
• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer — Completed
• Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) — Completed
• An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol — Completed